ESTIMATED
04/30/2024
04/30/2024
(AS OF MARCH 31)
Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
---|---|---|---|---|
Q1 2024 | 3 | $2.47 | $2.47 | $2.47 |
Q2 2024 | 12 | $2.40 | $3.11 | $2.79 |
Q3 2024 | 5 | $3.77 | $3.77 | $3.77 |
Q4 2024 | 5 | $4.52 | $4.52 | $4.52 |
Q1 2025 | 6 | $3.58 | $3.58 | $3.58 |
Q2 2025 | 6 | $3.86 | $3.86 | $3.86 |
Q3 2025 | 6 | $4.77 | $4.77 | $4.77 |
Q4 2025 | 6 | $2.70 | $2.70 | $2.70 |
Eli Lilly and Company last posted its earnings results on Tuesday, April 30th, 2024. The company reported $2.58 earnings per share for the quarter, topping analysts' consensus estimates of $2.46 by $0.12. The company had revenue of 8.77 B for the quarter and had revenue of 34.12 B for the year. Eli Lilly and Company has generated $6 earnings per share over the last year ($5.8 diluted earnings per share) and currently has a price-to-earnings ratio of 132.86. Eli Lilly and Company has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, August 8th, 2024 based on prior year's report dates.
Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue | 04/30/2024 | Q1 2024 | $2.46 | $2.49 | 0.03 | $8.94 B | $8.77 B | 02/21/2024 | Q4 2023 | $2.31 | $8.95 B | $9.35 B | 11/02/2023 | Q3 2023 | -$0.08 | -$0.06 | 0.02 | $9.50 B | 08/08/2023 | Q2 2023 | $1.98 | $1.96 | -0.02 | $8.31 B | 04/27/2023 | Q1 2023 | $1.73 | $1.49 | -0.24 | $6.86 B | $6.96 B | 02/22/2023 | Q4 2022 | $2.04 | $7.33 B | $7.30 B | 11/01/2022 | Q3 2022 | $1.92 | $1.61 | -0.31 | $6.94 B | 08/04/2022 | Q2 2022 | $1.69 | $1.06 | -0.63 | $6.49 B | 04/29/2022 | Q1 2022 | $2.11 | $7.81 B | 02/23/2022 | Q4 2021 | $1.81 | $7.69 B | $8.00 B | 10/27/2021 | Q3 2021 | $1.22 | $6.64 B | $6.77 B | 08/03/2021 | Q2 2021 | $1.89 | $1.53 | -0.36 | $6.60 B | $6.74 B | 04/30/2021 | Q1 2021 | $1.49 | $6.81 B | 02/17/2021 | Q4 2020 | $2.21 | $7.27 B | $7.44 B | 10/28/2020 | Q3 2020 | $1.33 | $5.88 B | $5.74 B | 07/31/2020 | Q2 2020 | $1.56 | $5.76 B | $5.50 B | 05/01/2020 | Q1 2020 | $1.60 | $5.86 B | 02/19/2020 | Q4 2019 | $1.56 | $5.91 B | $6.11 B | 10/25/2019 | Q3 2019 | $1.37 | $5.50 B | $5.48 B | 08/02/2019 | Q2 2019 | $1.44 | $5.58 B | $5.64 B |
---|
A. Eli Lilly and Company has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, August 8th, 2024 based off last year's report dates.
A. In the previous quarter, Eli Lilly and Company (NYSE:LLY) reported $2.58 earnings per share (EPS) to beat the analysts' consensus estimate of $2.46 by $0.12.
A. The conference call for Eli Lilly and Company's latest earnings report can be listened to online.
A. The conference call transcript for Eli Lilly and Company's latest earnings report can be read online.
A. Eli Lilly and Company (NYSE:LLY) has a recorded annual revenue of $34.12 B.
A. Eli Lilly and Company (NYSE:LLY) has a recorded net income of $34.12 B. Eli Lilly and Company has generated $5.82 earnings per share over the last four quarters.
A. Eli Lilly and Company (NYSE:LLY) has a price-to-earnings ratio of 132.86 and price/earnings-to-growth ratio is 11.63.